Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 5, 2005, Pages 908-913

  Autar, Reshma Saskia ^a,b   Boffito, Marta ^c   Hassink, Elly ^b   Wit, Ferdinand W N M ^b   Ananworanich, Jintanat ^a   Siangphoe, Umaporn ^a   Pozniak, Anton ^c   Cooper, David A ^a,d   Phanuphak, Praphan ^a,e   Lange, Joep M A ^a,b   Ruxrungtham, Kiat ^a,e   Burger, David M ^f  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e CHULALONGKORN UNIVERSITY   (Thailand)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Clinical pharmacology; HIV; Protease inhibitors; Thailand; United Kingdom

Indexed keywords

RITONAVIR; SAQUINAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; ETHNOLOGY; FEMALE; GENDER; GEOGRAPHIC DISTRIBUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OPEN STUDY; STATISTICAL SIGNIFICANCE; THAILAND; UNITED KINGDOM;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BODY MASS INDEX; BODY WEIGHT; DRUG THERAPY, COMBINATION; FEMALE; GEOGRAPHY; GREAT BRITAIN; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RITONAVIR; SAQUINAVIR; SEX CHARACTERISTICS; THAILAND;

EID: 27744594298     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki354     Document Type: Article

References (28)

1. Cardiello P, Srasuebkul P, Hassink E et al. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy. HIV Med 2005; 6: 122-8.
2. Lamotte C, Landman R, Peytavin G et al. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study). Antivir Ther 2004; 9: 247-56.
3. Cardiello PG, van Heeswijk RP, Hassink EA et al. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study. J Acquir Immune Defic Syndr 2002; 29: 464-70.
4. Gibaldi M. Pharmacokinetic variability - body weight, age, sex and genetic factors. In: Gibaldi M., ed. Biopharmaceutics and Clinical Pharmacokinetics. Philadelphia: Lea & Febiger, 1984; 206-27.
5. Kilby JM, Hill A, Buss N. The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: Combined analysis of pharmacokinetic data from 97 subjects. HIV Med 2002; 3: 97-104.
6. Chaillou S, Durant J, Garraffo R et al. Intracellular concentration of protease inhibitors in HIV-1-infected patients: Correlation with MDR-1 gene expression and low dose of ritonavir. HIV Clin Trials 2002; 3: 493-501.
7. Perloff MD, Von Moltke LL, Marchand JE et al. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci 2001; 90: 1829-37.
8. Gieschke R, Fotteler B, Buss N et al. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clin Pharmacokinet 1999; 37: 75-86.
9. Fletcher CV, Jiang H, Brundage RC et al. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group study 359. J Infect Dis 2004; 189: 1176-84.
10. Boffito M, Dickinson L, Hill A et al. Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: Comparison with the standard twice-daily regimen. Antivir Ther 2004; 9: 423-9.
11. Autar RS, Ananworanich J, Apateerapong W et al. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. J Antimicrob Chemother 2004; 54: 785-90.
12. Veldkamp AI, van Heeswijk RP, Mulder JW et al. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. J Acquir Immune Defic Syndr 2001; 27: 344-9.
13. van Heeswijk RP, Veldkamp AI, Mulder JW et al. Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: A pharmacokinetic pilot study. AIDS 2000; 14: F103-10.
14. Burger D, Boyd M, Duncombe C et al. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother 2003; 51: 1231-8.
15. Pfister M, Labbe L, Hammer SM et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group study 398. Antimicrob Agents Chemother 2003; 47: 130-7.
16. Cardiello PG, Monhaphol T, Mahanontharit A et al. Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects. J Acquir Immune Defic Syndr 2003; 32: 375-9.
17. Kurowski M, Arslan A, Moecklinghoff C et al. Effects of ritonavir on saquinavir plasma concentration: A preliminary analysis of 271 patients in routine clinical practice. Fifth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2000. Abstract P261A. AIDS 2000; 14 Suppl 4: S90.
18. Luber A, Anderson D, Stryker R et al. Can ritonavir (RTV) once daily boost saquinavir (SQV) twice daily? A pilot study. The XV International AIDS Conference. Bangkok, Thailand, 2004. MedGenMed. 2004, 11; 6(3): TuPeB4638 [eJIAS. 2004 11; 1(1):TUPeB4638].
19. Boyd MA, Aarnoutse RE, Ruxrungtham K et al. Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. J Acquir Immune Defic Syndr 2003; 34: 134-9.
20. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet 2003; 42: 107-21.
21. European Medicines Agency (EMEA). Invirase product information. EMEA-H-C-113-II-44-PI. http://www.emea.eu.int/humandocs/Humans/EPAR/ invirase/invirase.htm (29 June 2005, date last accessed).
22. Perry CM, Noble S. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection. Drugs 1998; 55: 461-86.
23. Kim K, Johnson JA, Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 2004; 44: 1083-1105.
24. Hesselink DA, van Schaik RH, van der Heiden IP et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-54.
25. Plosker GL, Scott LJ. Saquinavir: A review of its use in boosted regimens for treating HIV infection. Drugs 2003; 63: 1299-1324.
26. Schutz M GJ, Keh-Wei C, Montaner J. Lack of correlation between saquinavir trough levels and adverse events or clinical outcomes in the saquinavir cohort of the FOCUS Study. In: Program and Abstracts of the Forty-first Annual Meeting of the Infectious Diseases Society of America, San Diego, CA, USA, 2003. Abstract 654, p. 138. Infectious Diseases Society of America, Alexandria, VA, USA.
27. Eron JJ, Feinberg J, Kessler HA et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: A 48-week randomized clinical trial. J Infect Dis 2004; 189: 265-72.
28. Justesen U, FOX Z, Pedersen C et al. Pharmacokinetics from a 48-week randomised trial to evaluate safety and efficacy of indinavir/ritonavir 800/100 mg versus saquinavir/ritonavir 1000/100 mg: The MaxCmin1 trial. In: Ninth European AIDS Conference, Warsaw, Poland, 2003. Oral presentation and Abstract F2/5. http://www.eacs.ws/conference/ index_ns.htm (29 June 2005, date last accessed)